« Return to News | Clinical Intelligence

Morphotek to acquire samples from Fox Chase Cancer Center

Wednesday, January 11, 2012 11:13 AM

Morphotek has formed two agreements with Fox Chase Cancer Center to acquire clinical samples essential for the development and validation of companion diagnostic assays. The assays will be used in the identification of patients who will be suitable for treatment with targeted antibody therapeutics currently being developed by Morphotek.

“Fox Chase is a highly reputable organization with a well organized biorepository containing a bank of well annotated samples from a variety of cancer  types and the appropriate procedures and people in place to allow prospective studies and data management to take place," stated Dan O'Shannessy, Ph.D., director diagnostic development at Morphotek.  "We believe that with today's technology, the success or failure of a companion diagnostics program is governed by the quality of samples available for analysis.  The initiation of this project will be a significant step forward for our therapeutic development programs.”

Morphotek will provide funding for prospective and archival sample collection programs at Fox Chase to obtain samples from patients who are newly diagnosed with cancer or are being treated for a broad variety of tumor types.

Samples received from Fox Chase are being used in the development of companion diagnostic assays for Folate Receptor Alpha (FRA), the target of Morphotek’s lead therapeutic candidate, farletuzumb, which is currently being tested in several clinical trials against different types of cancers including non-small cell lung adenocarcinoma and ovarian carcinoma.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.